BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21385884)

  • 1. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
    Pinto C; Di Fabio F; Maiello E; Pini S; Latiano T; Aschele C; Garufi C; Bochicchio A; Rosati G; Aprile G; Giaquinta S; Torri V; Bardelli A; Gion M; Martoni A
    Ann Oncol; 2011 Nov; 22(11):2424-2430. PubMed ID: 21385884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
    Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M
    Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
    Aschele C; Cionini L; Lonardi S; Pinto C; Cordio S; Rosati G; Artale S; Tagliagambe A; Ambrosini G; Rosetti P; Bonetti A; Negru ME; Tronconi MC; Luppi G; Silvano G; Corsi DC; Bochicchio AM; Chiaulon G; Gallo M; Boni L
    J Clin Oncol; 2011 Jul; 29(20):2773-80. PubMed ID: 21606427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
    Dipetrillo T; Pricolo V; Lagares-Garcia J; Vrees M; Klipfel A; Cataldo T; Sikov W; McNulty B; Shipley J; Anderson E; Khurshid H; Oconnor B; Oldenburg NB; Radie-Keane K; Husain S; Safran H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):124-9. PubMed ID: 20947267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
    Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).
    Ricardi U; Racca P; Franco P; Munoz F; Fanchini L; Rondi N; Dongiovanni V; Gabriele P; Cassoni P; Ciuffreda L; Morino M; Filippi AR; Aglietta M; Bertetto O
    Med Oncol; 2013; 30(2):581. PubMed ID: 23606239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
    Valentini V; Coco C; Minsky BD; Gambacorta MA; Cosimelli M; Bellavita R; Morganti AG; La Torre G; Trodella L; Genovesi D; Portaluri M; Maurizi-Enrici R; Barbera F; Maranzano E; Lupattelli M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):403-12. PubMed ID: 17919844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
    Glynne-Jones R; Mawdsley S; Harrison M
    Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
    Hospers GA; Punt CJ; Tesselaar ME; Cats A; Havenga K; Leer JW; Marijnen CA; Jansen EP; Van Krieken HH; Wiggers T; Van de Velde CJ; Mulder NH
    Ann Surg Oncol; 2007 Oct; 14(10):2773-9. PubMed ID: 17653805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).
    Pinto C; Di Bisceglie M; Di Fabio F; Bochicchio A; Latiano T; Cordio S; Rosati G; Aschele C; Marino A; Bergamo F; Bustreo S; Frassineti L; Ciardiello F; Damato A; Giaquinta S; Baldari D; Boni L
    Oncologist; 2018 Aug; 23(8):912-918. PubMed ID: 29523646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
    Gérard JP; Chapet O; Nemoz C; Romestaing P; Mornex F; Coquard R; Barbet N; Atlan D; Adeleine P; Freyer G
    J Clin Oncol; 2003 Mar; 21(6):1119-24. PubMed ID: 12637479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
    Foxtrot Collaborative Group
    Lancet Oncol; 2012 Nov; 13(11):1152-60. PubMed ID: 23017669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.
    Caravatta L; Padula GD; Picardi V; Macchia G; Deodato F; Massaccesi M; Sofo L; Pacelli F; Rotondi F; Cecere G; Sallustio G; Di Lullo L; Piscopo A; Mignogna S; Bonomo P; Cellini N; Valentini V; Morganti AG
    Acta Oncol; 2011 Nov; 50(8):1151-7. PubMed ID: 21851185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
    Machiels JP; Duck L; Honhon B; Coster B; Coche JC; Scalliet P; Humblet Y; Aydin S; Kerger J; Remouchamps V; Canon JL; Van Maele P; Gilbeau L; Laurent S; Kirkove C; Octave-Prignot M; Baurain JF; Kartheuser A; Sempoux C
    Ann Oncol; 2005 Dec; 16(12):1898-905. PubMed ID: 16219623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
    Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
    Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study.
    Lee WS; Baek JH; Shin DB; Sym SJ; Kwon KA; Lee KC; Lee SH; Jung DH
    Int J Clin Oncol; 2013 Apr; 18(2):260-6. PubMed ID: 22350021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
    Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
    Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.